fumaric-acid and Chronic-Disease

fumaric-acid has been researched along with Chronic-Disease* in 2 studies

Trials

1 trial(s) available for fumaric-acid and Chronic-Disease

ArticleYear
[Comparative efficacy of nitrofurans in children and adolescents with pyelonephritis in presence of crystalluria].
    Terapevticheskii arkhiv, 2013, Volume: 85, Issue:12

    To evaluate the efficacy of nitrofurans in children and adolescents with pyelonephritis in the presence of crystalluria.. The study included 50 patients aged 4-14 years with chronic pyelonephritis in the presence of dysmetabolism. The patients underwent general blood test, general urinalysis with an urocytogram, bacteriological examination of urine, biochemical test of serum (uric acid, calcium, phosphorus, magnesium, urea, and creatinine) and 24-hour urinary excretion (uric acid, oxalates, calcium, phosphorus, and magnesium) at hospital admission and over time. The treatment regimen for Group 1 patients after antibiotic therapy involved furamag, Group 2 received furagin. The drugs were used in a dosage of 2 mg/kg/day in 2 divided doses for 14 days. Complaints, major clinical manifestations, crystalluria patterns, and a number of laboratory findings were analyzed over time.. The urinary sediment showed leukocyturia and bacteriuria in all the patients, oxaluria in 70% of the patients, uraturia in 10%, and mixed crystalluria in 20%. The main etiological agent of pyelonephritis was Escherichia coli (48.4%). Increased serum uric acid concentrations were revealed in 14% of the patients. Daily urine tests revealed hyperoxaluria, hyperuricosuria, and hypercalciuria in 86, 18, and 8% of the patients, respectively; urinary magnesium excretion was reduced in 86%. After treatment, Group 1 patients showed a more marked therapeutic effect in terms of a number of indicators (leukocyturia, crystalluria, uricosuria, magnesuria).. The results of the study showed that the antibacterial therapy involving antibiotics and nitrofurans for an exacerbation of chronic pyelonephritis in the presence of crystalluria not only provides an anti-inflammatory effect, but also leads to reductions in the level of crystalluria and the urinary content of uric acid and calcium. There was a significantly marked reduction in crystalluria, serum uric acid, and urinary oxalates and calcium in the children taking furamag. Out of nitrofurans, furamag may be recommended as the drug of choice to treat urinary tract infections in the presence of crystalluria.

    Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Chronic Disease; Crystallization; Female; Fumarates; Furagin; Humans; Male; Pyelonephritis; Treatment Outcome; Urinary Calculi

2013

Other Studies

1 other study(ies) available for fumaric-acid and Chronic-Disease

ArticleYear
[Acute kidney failure during psoriasis therapy with fumaric acid derivatives].
    Deutsche medizinische Wochenschrift (1946), 1990, Jun-29, Volume: 115, Issue:26

    24 days after starting treatment of psoriasis with fumaric acid derivatives (0.8-1.0 g orally, plus unknown quantities locally) a 21-year-old woman developed acute oliguric renal failure with a rise of serum creatinine levels to 1094 mumol/l (12.4 mg/dl). Deterioration of renal function had been preceded by severe abdominal symptoms with nausea, vomiting and colicky pain. On admission to hospital she was dehydrated with hyponatraemia and hypokalaemia. There was glomerular microhaematuria, increased excretion of renal epithelia, and tubular proteinuria. Renal biopsy demonstrated acute tubular damage with vacuolization of proximal epithelia, dilated tubules and scattered necroses. After intermittent haemodialysis (13 courses over two weeks) renal function gradually recovered, as demonstrated at a follow-up examination four months after discharge.

    Topics: Acute Kidney Injury; Adult; Biopsy; Chronic Disease; Drug Combinations; Drug Therapy, Combination; Female; Fumarates; Humans; Kidney; Powders; Psoriasis

1990